Quick Answer
Bluejay Diagnostics, Inc. reported Research And Development Expense of $3.05 million for the year ending 2025.
- Bluejay Diagnostics, Inc. showed a decrease of -12.2% in Research And Development Expense from 2024 to 2025.
- This data is from Bluejay Diagnostics, Inc.'s annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $2.7 thousand | Q1 2021: $24.2 thousand | Q2 2021: $226.0 thousand | Q3 2021: $442.5 thousand | Q1 2022: $694.8 thousand | Q2 2022: $756.3 thousand | Q3 2022: $1.38 million | Q1 2023: $1.35 million | Q2 2023: $1.68 million | Q3 2023: $1.40 million | Q1 2024: $1.33 million | Q2 2024: $1.03 million | Q3 2024: $551.7 thousand | Q1 2025: $784.8 thousand | Q2 2025: $889.9 thousand | Q3 2025: $785.6 thousand.
- Over the full 6 years of available data (2020 to 2025), Bluejay Diagnostics, Inc.'s Research And Development Expense has grown by 477.8%.
- Historical annual values: Fiscal year 2025: $3.05 million | Fiscal year 2024: $3.47 million | Fiscal year 2023: $5.71 million | Fiscal year 2022: $4.15 million | Fiscal year 2021: $1.15 million | Fiscal year 2020: $527.3 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: